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Background: Pharmaceutical products are an important component of expenditure on public health insurance in
the Federal Republic of Germany. For years, German policy makers have regulated public pharmacies in order to
limit the increase in costs. One reform has followed another, main objective being to increase competition in the
pharmacy market. It is generally assumed that an increase in competition would reduce healthcare costs. However,
there is a lack of empirical proof of a stronger orientation of German public pharmacies towards competition thus
far.
Methods: This paper analyses the self-perceptions of owners of German public pharmacies and their orientation
towards competition in the pharmacy markets. It is based on a cross-sectional survey (N = 289) and distinguishes
between successful and less successful pharmacies, the location of the pharmacies (e.g. West German States and
East German States) and the gender of the pharmacy owner. The data are analysed descriptively by survey items
and employing bivariate and structural equation modelling.
Results: The analysis reveals that the majority of owners of public pharmacies in Germany do not currently
perceive very strong competitive pressure in the market. However, the innovativeness of the pharmacist is
confirmed as most relevant for net revenue development and the profit margin. Some differences occur between
regions, e.g. public pharmacies in West Germany have a significantly higher profit margin.
Conclusions: This study provides evidence that the German healthcare reforms aimed at increasing the
competition between public pharmacies in Germany have not been completely successful. Many owners of public
pharmacies disregard instruments of active customer-orientated management (such as customer loyalty or an
offensive position and economies of scale), which could give them a competitive advantage. However, it is clear
that those pharmacists who strive for systematic and innovative management and adopt an offensive and
competitive stance are quite successful. Thus, pharmacists should change their attitude and develop a more
professional business model.Introduction
The Federal Republic of Germany has one of the most
expensive health care systems in the world. The expend-
iture on health in 2010 amounted to EUR 287.3 billion
or EUR 3,510 per capita, representing approximately
11.6% of the gross domestic product, with the vast ma-
jority (57.6%) borne by statutory health insurance [1]. A
major cost factor (EUR 40.9 billion in 2010 or 14.2% of
the total healthcare costs in 2010 [1]) is expenditure on
pharmaceutical products. Consequently, the German* Correspondence: steffen.flessa@uni-greifswald.de
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distribution, and reproduction in any mediumGovernment has taken regulatory action and presented a
number of healthcare reforms, aiming – at least partly –
at containing the cost of pharmaceutical products. Most
prominently, the “GKV-Modernisierungsgesetz” (Moder-
nization Act for the Statutory Health Insurance System,
GMG 2004) and the “Arzneimittelmarkt-Neuordnungs-
gesetz” (Law on the Reorganization of the Pharmaceut-
ical Market, AMNOG 2011) were introduced to increase
(inter alia) competition among public pharmacies.
German policy makers assume that competition in the
pharmaceutical markets will reduce the costs of the
healthcare sector. Thus, public pharmacies should compete
for consumers by employing instruments of modern mar-
keting, providing high-quality services based on modernCentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ent target groups and implementing professional distribu-
tion policies including the most appropriate location and
transport services. Thus, public pharmacists should apply
instruments of active customer-orientated management
(strategic management). Some authors postulate that the
healthcare reforms of the last ten years have increased the
orientation of public pharmacists towards competition and
the application of strategic management. For instance, Star-
gardt, Schreyögg, and Busse [2] demonstrated that the
GMG had an impact on the retail prices of five selected
over-the-counter (OTC) products. However, there is no evi-
dence that this impact is a matter of fact for all pharmacies
and their complete spectrum of products [3-6].
This paper analyses the perceived economic situation
as well as the competitive behaviour of public pharma-
cies in the outpatient sector in Germany. It examines
the effects of the competitive situation, innovativeness,
location and willingness to co-operate on commercial
success and draws conclusions in relation to the need
and readiness to use strategic methods of business man-
agement in pharmacies. For this purpose, the next sec-
tion provides some basic information on the German
healthcare system. Subsequently, the methodology is
presented. This is followed by the results and discussion.
Background
The following analysis refers exclusively to the pharmaceut-
ical expenditure of the statutory health insurance sector in
Germany based on the “Sozialgesetzbuch V” (Social Act V,
SGB V), i.e. the special rules for the proportion of the
German population within private insurance – approxi-
mately 15% (about 12 million out of the total population of
82.3 million) – are not reflected. Statutory health insurance
in Germany is based on several principles relevant to this
analysis. Most importantly, in every budget period the in-
come of the insurance must recover the costs. Thus, in-
creasing costs will result in the raising of the contribution
rate, which is not seen as favourable for the economy.
In addition, the individual risk of disease (e.g. previous
illnesses, age) has no influence on the contribution rate.
However, health insurance expenditure does not comprise
the total expenditure on health. For example, private
households have to make a co-payment for drugs them-
selves and a significant proportion of the expenditure on
medicines is not recoverable. Most patients obtain their
pharmaceutical products from a public pharmacy. A
minor share is provided by institutional pharmacies (e.g. a
hospital pharmacy after admission) or is purchased from
normal retail shops. Drugs are frequently prescribed by
physicians and these can only be bought from public
pharmacies. In principle, the health insurance pays for the
pharmaceutical products, but there are a number of
exemptions.First, prescribed drugs are subject to a surcharge
amounting to 10% of the pharmacy sales price with a
minimum of EUR 5 and a maximum of EUR 10 per
package. Secondly, non-prescription OTC drugs which
are sold in pharmacies have essentially been excluded
from reimbursement since 2004 (with the exception of a
list of non-prescription drugs that are reimbursed). Drugs
sold at normal retail shops are non-prescription and are
not paid for by the insurance.
Expenditure on healthcare services has grown steadily
and there is a strong literature explaining the causes, such
as medical-technical progress and demographic develop-
ments [7,8]. In particular, the influence of age, both on mor-
bidity and the consumption of pharmaceutical products, is
of considerable relevance in the increase in healthcare costs
and the consumption of pharmaceuticals [9]. The group of
insured persons above the age of 60 constitutes 26.8% (all
figures from 2008) of the insured population, but accounts
for 54% of the expenditure on pharmaceutical products cov-
ered by statutory health insurance [10]. In contrast, the con-
tributions of this group of insured persons cover only 22.1%
of the income of statutory health insurance [11].
From 1991 to 2009, the share of the population above
65 years increased from 14.9% to 20.7% [1]. By 2060, the
population in the 65+ age group is expected to comprise
a share of 34% [12], so that we can expect increasing
expenditure on pharmaceutical products. Consequently,
health policy makers frequently call for increased effi-
ciency in pharmaceutical markets and design healthcare
reforms accordingly.
The fundamental assumption of all healthcare reforms
in Germany is that public pharmacies competing in ra-
ther free markets will serve their customers better and
at a more favourable price than in a market where the
legislator prohibits competition. Traditionally, the prices
of pharmaceutical products were fixed in Germany.
Pharmacists could only compete with others by offering
good consultation services to their clients and they could
not transfer their innovative concepts to other pharma-
cies because each pharmacist was allowed to operate
only one pharmacy (prohibition of multiple ownerships).
Mail-order business was also prohibited.
Since 2004, the legislator has abolished these restric-
tions to enhance competition. For instance, pharmacy
owners have been allowed to operate up to three further
public pharmacies (so-called branch pharmacies) in
addition to their main pharmacy. At the same time,
mail-order purchases have become possible. The only
major restriction that has not yet been abolished is the
prohibition of third-party ownership, i.e. only profes-
sional pharmacists with a university degree in pharma-
ceutics and an additional internship are allowed to own
and run public pharmacies. This condition was recently
endorsed by the European Court of Justice.
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so-called combi-model. Pharmacists receive a fixed phar-
macy fee and a linear mark-up of 3% for pharmaceutical
products per package. From 2004, the fixed pharmacy
fee was EUR 8.10, but it was recently cut back by a phar-
macy discount of EUR 2.30. Since 2004, the prices of
OTC products have been based on a regressive mark-up
scheme. Therefore, price competition is only feasible
outside the assortment of prescribed pharmaceutical
products. In principle, prescribed drugs cost the same
for healthcare insurance and for the patient in every
pharmacy in Germany. Thus, competition must focus on
services, information, location and customer orientation.
However, we do not know whether the Government’s
intention to increase competition is actually perceived
by the pharmacists and whether these reforms are hav-
ing any impact on their management practices. This
study was designed to provide some insights into the im-
pact of the healthcare reforms on the management of
public pharmacies.
Methods
The analysis in this study is based on a questionnaire
asking for facts, opinions and perceptions of pharmacists
running public pharmacies in the Federal Republic of
Germany. Mail-order pharmacies were not included. If a
pharmacist runs more than one outlet, each outlet is
counted as a separate public pharmacy.
The questionnaire included closed and open questions.
After a pre-test, 10% of German public pharmacies
(i.e. 2,168 out of 21,679 pharmacies) were randomly
selected and contacted in writing. To ensure a sufficient
response rate, all seventeen Regional Chambers of
Pharmacists were informed of the study and asked for
their support. The survey was undertaken from June to
October 2008. Four to six weeks after the respective
dispatch date, a reminder was sent to the pharmacists.
In cases where e-mail addresses were available, the re-
minder was sent electronically for reasons of cost; both
the questionnaire and the voucher were provided as PDF
files. In the case of reminders by letter, the pharmacists
were given the possibility of downloading the question-
naire. Due to the anonymity afforded to the respondents,
reminders had to be sent to all the pharmacists.
The questionnaire comprised 37 questions (see Additional
file 1) including:
 Duration of existence of pharmacy
 Establishment/take-over mode
 Multiple ownership (if any)
 Localization of pharmacy
 Size of catchment population
 Local purchasing power
 Planned or actual change of location Competitive position (perceived number of
competitors, perceived competitive pressure,
evaluation of own competitive position)
 Attitude towards competitors (offensive attitude)
 Willingness or plans for cooperation
 Active customer-orientated management
 Success factors (net revenue development, profit
margin)
 Frequency of recommendation of pharmaceutical
products for self-medication and information on
best-selling self-medication areas
 Sales and turnover of different segments (economies
of scale)
 Personal assessment of regulations in the pharmacy
market
The central theoretical basis of the confirmatory study is
the search for success factors [13-15]. Furthermore, our
research is based on concepts of indirect performance
measurement, primarily competitive forces and the indus-
try structure analysis of Porter [16,17] with its starting
points of the market-based view and the resource-based
view. The central methodological positioning is based on
Popper’s propensity model [18].
The analysis was performed using uni-, bi- and multivari-
ate models for the different items, as well as structural
equation modelling (SEM). The main statistics used were
Spearman’s rank correlation (R), the chi-square test and the
Mann–Whitney U test. These procedures are standard in
economic and social research and can be used even in the
case of inhomogeneous data dispersions and when the level
of measurement is relatively low (i.e. ordinal data). The stat-
istical analysis presents the perceived competitive pressure,
a number of selected hypothesis tests between “Economic
Success” and geographical pattern, business performance,
active customer-orientated management, and finally co-
operation strategy.
In addition, we developed a SEM [19] in order to
confirm the importance of each factor influencing the
economic success of public pharmacies. The focus of the
statistical analysis is the construct “Active Customer-
Orientated Management”, represented by the indicators
“General Intention to Develop”, “Customer Loyalty”,
“Development of Customer Orientation/Customer Loy-
alty”, “More Innovation” and “Offensive Attitude”, the
opposite to defensive attitude [20] . We also analyses the
relation between these indicators and economic success.
The H0-hypothesis between the construct economic
success and the indicators was in all cases that there is no
causality. We estimated the SEM using nonlinear universal
relational modelling (NEUSREL) [21,22] as we were pri-
marily working with ordinal data and therefore on the
level of measurement defined above. The ordinal data did
not allow the application of standard procedures but
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complex models in a structural-analytical way [23]. This is
one reason for preferring NEUSREL as unlike the most
popular statistical packages, LISREL and AMOS, a mix of
scales (nominal, ordinal or metric) is allowed and Gauss-
ian distribution is not assumed. NEUSREL is based on the
statistical package PLS with additional features and Bayes-
ian neural networks [21,24,25]. For example, NEUSREL is
able to identify unknown paths, model interaction be-
tween monitored or manifest and unmonitored or latent
variables and identify unknown nonlinearities [21,22].
Another essential component is the SEM process. This
process focused on two steps, the estimation of the
measurement model and the fitting of the SEM. In our
pragmatic model development approach, we combined
confirmatory and exploratory purposes. There is no prior
empirical study with conceptualized latent variables. For
these – exploratory – purposes a soft modelling package
with soft or relaxed assumptions about data is used. An
alternative modelling approach was not indicated by the
current state of research. However an accepted model is
only a confirmed or not-disconfirmed model.
A further important reason for choosing a variance-
based modelling and variance-based statistical package
respectively is the requirements of a small representa-
tive sample. The literature gives no uniform measure-















Figure 1 Structural Equation Model (SEM).multivariate and structural-analytical aims, the recom-
mendations in the literature vary considerably, from at
least 100 (or preferably 200) to five cases per parameter
to be estimated, or a relation of 2:1 between parameters
to be estimated and case number [26,27]. In the context
of PLS, Chin indicates a heuristic with the relation 10:1
between parameters to be estimated and case number,
or the decuple of the largest quantity of indicators [28].
A sample of less than 100 is indicated as appropriate in
the literature in the context of PLS [29], but with the
proviso that “PLS is not a silver bullet to be used with
samples of any size!” [30]. The conditions stated re-
garding sample size were fulfilled in our empirical ana-
lysis, which drew on data from 289 German pharmacies
(see the Results section below).
As Figure 1 shows, we assume that the economic suc-
cess of public pharmacies is determined to a consider-
able extent by the competitive environment being a
composite of the number of competitors, competitive
position and competitive pressure. Furthermore, we
assume that large pharmacies and pharmacies with a
high purchasing capacity realize an economically stron-
ger development. We also suppose that public pharma-
cies with more innovation, an offensive attitude towards
competitors and a general customer-orientated strategy
(and with a focus on OTC products, measured as a share
















Table 1 Baseline characteristics of the sample
%
Number of inhabitants at
the location
< 5,000 18.20
5,000 – 10,000 20.60
10,000 – 50,000 32.10
50,000 – 100,000 8.40
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posite reliability and average variance extracted (AVE) to
describe the fit of the model. Cronbach’s alpha coeffi-
cient is one of the most widely used estimators for the
reliability of tests and a measure of internal consistency
or reliability [31,32]. If the test is not unidimensional, it
is likely that the true reliability will be underestimated
[33]. In exploratory cases, a value equal to or higher
than 0.6 for the Cronbach’s alpha coefficient is consid-
ered satisfactory [34,35]. As Cronbach’s alpha coefficient
is only allowed under the assumption of linearity and
equal loadings for all manifest variables [26,32,36], com-
posite reliability can be considered a better criterion for
reliability [28]. Composite reliability above 0.7 indicates
high reliability [33,36]. However, Bagozzi [37] and other
authors [38] have accepted a minimum level of 0.6.
Cronbach’s alpha coefficient and composite reliability
are instruments used to measure the compliance of re-
flective indicators. The third model parameter, the AVE,
measures the amount of variance that is captured by the
construct. The AVE should be a minimum level of more
than 0.5 [37-39].
Finally we use a less common parameter, Scott’s homo-
geneity ratio, which measures the average inter-item cor-
relation. If Scott’s homogeneity ratio is approximately zero,
then the manifest variables do not distinguish the con-
structs (or latent variables). If Scott’s homogeneity ratio is
less than 0.4 or between 0.2 and 0.4, it is considered accept-
able [40,41].
Results
The results are presented in several sub-sections. We start
with a description of the sample. We then provide some
insights into the perceived competitive pressure in relation
to public pharmacies in Germany. This is followed by a
number of bivariate analyses (geographical pattern, busi-
ness orientation) and the results derived from the SEM.
Description of the sample
Of the 21,679 stationary public pharmacies (at the time
of the study, excluding mail-order pharmacies and in-
cluding branches), 10% were randomly selected. In total,
291 pharmacies responded and 289 (13.33%) question-
naires could be used. Therefore, 1.33% of the established
pharmacies in Germany contributed to the insights pro-
vided in this study. We consider this a rather strong
sample size in comparison to the above-mentioned
requirements.
The correlation between our study sample and the
population in each state is highly significant (Spearman
rank R = 0.87, p < 0.001). Thus, the sample can be con-
sidered geographically representative. Table 1 shows
some baseline characteristics of the sample of public
pharmacies in Germany.Unfortunately, no official statistics on the gender of
pharmacists running public pharmacies exist. Conse-
quently, it is difficult to assess whether our sample is
representative. The association of German pharmacists,
ABDA, provides data on the gender ratio of this profes-
sion, irrespective of whether they are employed or run
their own pharmacies [42]. According to these statistics,
33.4% of German pharmacists are male, 66.6% are female
(year 2007). Our own sample shows that 56.7% of pharma-
cists running a public pharmacy are male, 43.3% female.
However, these figures cannot be compared as it is likely
that a higher proportion of male pharmacists run their
own public pharmacies than female pharmacists.
Competition
A number of questions aimed to determine the per-
ceived level of competition in the public pharmacy mar-
ket in Germany. As Table 2 shows, the number of direct
competitors in the catchment area of public pharmacies
is still limited. The majority of pharmacies have three or
fewer competitors, although a few have more than ten.
Consequently, most public pharmacies view their own
position in the market as acceptable or good and per-
ceive the pressure from their main competitor as moder-
ate or even low. There is no single year in which the
competitive pressure increased dramatically, but the
GMG (2004) seems to have had the greatest impact on
the competitive situation. The responses of the public
pharmacists on the (limited) increase in competitive
pressure are quite conservative. They try to gain a com-
petitive edge by providing high-quality consultancy ser-
vices to their clients and offering some after-sales
services, such as transport.
Table 2 Perceived competition on German public
pharmacy market (rounded)
Question Mode
How many public pharmacies are
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tion in the public pharmacy market is not as high as one
would expect. Even after a series of laws aimed at in-
creasing the competition, the majority of pharmacists
are still in a situation of “smooth” water.
Geographical pattern
Based on this sample, we undertook a number of bivari-
ate analyses in order to determine the correlation be-
tween parameters. In a first step, we determined the
impact of the location of a public pharmacy on business
performance. For instance, we wanted to know whether
there is any significant difference in terms of economic
success between public pharmacies in East Germany
(the former German Democratic Republic) and WestGermany. The hypothesis that there would be no differ-
ence was tested by comparing the location (West vs.
East) with the net revenue development and profit mar-
gin of public pharmacies. Based on a non-parametric
Mann–Whitney U test, we can show that there is no
systematic pattern in the effect on net revenue develop-
ment (transformed Z-value from the U test, absolute =
0.15, p = 0.44 one-way; two-sided testing results in the
same conclusion, p = 0.88). However, there is a signifi-
cant effect on the profit margin, namely that for public
pharmacies in West Germany (N = 218) a higher profit
margin was quoted than for public pharmacies in East-
ern Germany (N = 52) (transformed Z-value from the U
test, absolute = 2.0; p < 0.05 one-way; two-sided testing
results in the same conclusion, p < 0.05).
In addition, we wanted to examine whether there are any
geographical differences concerning forms of cooperation.
For this element of the analysis, we distinguish between
North (Schleswig-Holstein, Brandenburg–Berlin, Hamburg,
Saxony-Anhalt, Bremen, Lower Saxony, Mecklenburg–
Western Pomerania, and North Rhine-Westphalia) and
South (Bavaria, Baden-Württemberg, Saarland, Rhineland-
Palatinate, Hessen, Thuringia, and Saxony), as well as
between East and West Germany. According to the Mann–
Whitney U and the chi-square tests, there was no geo-
graphic pattern in terms of cooperation as actually
practiced by the pharmacists, either for East–West
(chi-square = 6.4, df = 4, p = 0.17), or for North–South
(chi-square = 6.4, df = 4, p = 0.17), or for North–South with-
out the Eastern States (chi-square = 1.5, df = 4, p = 0.82).
The relevant statistical tests merely confirm a uniform level
of cooperation 22 years after German reunification in all
parts of the country.
In addition, we expected that the turnover of public
pharmacies in rural places would be much lower than in
cities [43,44]. However, the data do not support this hy-
pothesis. The variables “Population Size” and “Turnover”
were not significantly correlated (chi-square = 1.9, df = 2
at N = 226, p = 0.38). Also, the status of “Major City”
showed no link with the turnover of the pharmacies sur-
veyed. A further inspection of the data revealed that the
highest turnover tends to be achieved in smaller and
medium-sized locations, but this is not significant. This
result corresponds to the findings of Schöffski [45]. How-
ever, Schöffski’s study focused on the implementation of
regulation and deregulation measures for pharmaceutical
products and included only descriptive statistical analysis.
Business performance
Based on economic theory, we would expect a correl-
ation between the competitive environment and the
business performance of a public pharmacy, i.e. strong
competition should have a negative influence on turn-
over and the profit margin. Based on our survey, the
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of relevant competitors (stated by pharmacists) with net
revenue development and the profit margin (“Economic
Success”). However, it seems that none of these outcome
parameters is significantly correlated with the number of
competitors. However, when we asked the pharmacists
about their perceptions of competitive pressure, the
results changed. The perceived competitive environment
in the pharmacy market was significantly negatively
correlated with business performance (R =−0.38, p < 0.001;
R = −0.26, p < 0.001). The perceived competitive pressure
from main competitors showed the same result (R = −0.30,
p < 0.001; R = −0.20, p < 0.001). It therefore seems that the
number of competitors is no indicator of competitive pres-
sure and that for many pharmacists competition is still not
an issue at all.
In addition, we would expect that the purchasing
power of the catchment population would have a strong
impact on the business performance of public pharma-
cies, in particular in the self-medication segment [45,46].
First, we analysed the relationship between purchasing
power and the share of OTC and prescribed drugs in
total turnover. As expected, there is a positive and statis-
tically significant correlation between purchasing power
and OTC turnover as a share of total turnover (R = 0.21,
p < 0.01). At the same time, the relationship between
purchasing power and the turnover of prescribed medi-
cines as a share of total turnover became clearly negative
(R = −0.33, p < 0.001). In other words, public pharmacies
rely strongly on prescribed drugs in catchment areas with
poor purchasing power, such as in Eastern Germany.
Second, we analysed whether the perceived import-
ance of the OTC segment (asked by the question “How
often do you recommend non-prescribed pharmaceuti-
cals for self-medication when advising customers?”) has
an influence on the profit margin. We can confirm that
the orientation towards OTC has an impact on the profit
margins of public pharmacies (R = 0.22, p < 0.001).
Third, we directly related the purchasing power of the
catchment areas to business performance. As expected,
net revenue development correlated positively with pur-
chasing power (R = 0.14), but it was not significant. The
relationship between profit margin and purchasing
power was even weaker (R = 0.04). Thus, competition for
OTC clients with strong purchasing power is of rele-
vance for the public pharmacies, but generally the busi-
ness performance of German public pharmacies does
not depend strongly on the purchasing power of its
catchment population.
Another assumption of business administration is that
a bigger business unit will have a higher profit margin:
the fixed costs of a public pharmacy are high so in-
creased sales will reduce the cost per unit and increase
the profit per unit. We used turnover and number ofemployees as proxies for the size of the pharmacy. Our
results support this assumption as the turnover of the
pharmacy and the profit margin are highly and signifi-
cantly correlated (R = 0.23, p < 0.001). The same results
hold true if the number of employees is taken as a proxy
of size (R = 0.68, p < 0.001).
Active customer-orientated management
One would expect that pharmacists demonstrating
greater innovativeness, good levels of customer consult-
ation and other services and a higher marketing orienta-
tion would have stronger revenue increases and a higher
profit margin. Consequently, we asked the pharmacists
for their self-assessment of their innovativeness (“More
Innovation”), the quality of their customer services and
their marketing orientation in comparison with their
competitors. As Table 3 shows, revenue development
correlates to self-perceived innovativeness, customer
consultation, other customer services, marketing orien-
tation, offensive attitude, general intention to develop
and development of customer orientation/loyalty. Only
the indicator “More Innovation” is correlated with both
success criteria. However, the correlation is lower and
by far less likely to be significant for the profit margin
than for revenue development.
Customer consultation, customer service and mar-
keting orientation represent the indicator “Customer
Loyalty” in the SEM. The dimension “Development of
Customer Orientation/Loyalty” covers the self-perceived
intention to extend customer satisfaction (e.g. through
personnel training) and the organization of events for
customers/patients concerning health-related topics.
Cooperation strategy
A final strategic option is cooperation with other public
pharmacies. In “normal” markets, one would expect that
cooperating business units would have higher turnover
and profit margins. However, our analysis detected no
systematic relationships between cooperation intensity
and profit margins (R = 0.09, N = 276, p = 0.08). Likewise,
there are no homogeneous or drastic correlations be-
tween the degree of cooperation and the various consid-
erations of turnover share surveyed. In detail, the results
are as follows, broken down by turnover share:
 Turnover, supplementary range (body care
products/food supplements): R = −0.09, N = 208,
p = 0.11, one-way.
 Prescription turnover (prescription pharmaceuticals):
R = 0.03, N = 210, p = 0.32, one-way.
 Prescription turnover (OTC pharmaceuticals):
R = −0.12, N = 192, p < 0.05, one-way.
 Final consumer sales (OTC pharmaceuticals):
R = 0.10, N = 198, p = 0.08, one-way.





More innovation R = 0.37 R = 0.28
N = 274 N = 266
p < 0.001 p < 0.05
Customer consulting R = 0.2 R = 0.11
N = 273 N = 265
p < 0.001 p < 0.05
Customer service R = 0.23 R = 0.18
N = 274 N = 266
p < 0.001 p < 0.01
Marketing orientation R = 0.3 R = 0.09
N = 273 N = 265
p < 0.0012 p < 0.07
Offensive attitude R = 0.21 R = 0.05
N = 279 N = 271
p < 0.001 p < 0.19
General intention to develop R = 0.25 R = 0.18
N = 280 N = 271
p < 0.001 p < 0.01
Development of customer
orientation/loyalty
R = 0.21 R = 0.11
N = 282 N = 273
p < 0.001 p < 0.05
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As described in the methodology, the SEM was used to
determine the importance of the different factors influ-
encing the business success of public pharmacies. The
model, as given in Figure 2, is acceptable with a GoF
(Goodness of Fit) of R2 = 42% with ten iterations [21].
The most important model parameters are presented in
Table 4.
The SEM shows no clear-cut distinction between the
different criteria. The minimum level for Cronbach’s
alpha coefficient in exploratory cases, according to
Bagozzi [35,37] and Nunnally [34], and Scott’s homogen-
eity ratio [40,41] are completely fulfilled.
For both criteria, the composite reliability and the AVE,
the construct “Active Customer-Orientated Management”
is critical. It should be noted that the value for the com-
posite reliability for the construct “Active Customer-
Orientated Management” at 0.55 is borderline. Therefore,
it must be acknowledged that this result does not meet
the ideal condition (here GFO/R2 > 50%; Cronbach’s alpha
coefficient ≥ 0.6; composite reliability ≥ 0.6; AVE ≥ 0.5 and
Scott’s homogeneity ratio ≥ .2). As this is the first SEM
exercise in the pharmacy field in Germany, the results are
relative. It is the starting point for further analysis and thevalues of the different quality criteria presented can be
judged adequate for the purposes of an exploratory study.
The SEM, calculated with NEUSREL [21,22] using 11
variables and standardized correlations, is shown in
Figure 2. The model expresses a set of important partial
hypotheses concerning direct and indirect relations
between monitored or manifest and unmonitored or la-
tent variables. The rectangles represent manifest vari-
ables – for example sales profitability – and the ovals
represent the latent variables, which are abstract reflect-
ive constructs, with the different variables or indicators
[20]. Solid arrows indicate hypothesized direct effects
and broken arrows indicate indirect significant effects.
In the case of OTC focus, a single item with a factor
status is involved. In addition, Figure 2 depicts the correl-
ation between the dimensions and the respective latent
constructs. The significantly negative correlation between
perceived competitive pressure and business performance
(R = −0.38, p < 0.001; R = −0.26, p < 0.001) based on the
univariate-level analysis changed in the SEM to a small
non-significant direct effect. Otherwise the model identi-
fies two additional indirect effects, especially that between
turnover/volume and active customer-orientated manage-
ment. In contrast to this effect, the competitive environ-
ment and the turnover/volume indicate no substantial
relationship. This may be a reflection of the regulations
within the German pharmacy market outlined in the
introduction to this paper, i.e. the neutralization of com-
petitive action.
Finally, Table 5 shows that some indirect effects
between the latent constructs were not significant.
Discussion
The public pharmacy market in Germany is undergoing a
process of deregulation. This is predicted to increase com-
petitive pressure and raise the competitive orientation of
pharmacies. The literature states that there should be
growing competition and that this should have an impact
on the business orientation of pharmacists [3-6,45], but
there is no proof of this. This paper has presented the first
empirical cross-sectional survey (N = 289) of the competi-
tive orientation of public pharmacies in Germany since
the start of deregulation.
The analysis shows that there is no North–South or
East–West dichotomy to any great extent. Thus, we can-
not detect aspects of competitiveness that determine
economic success in relation to particular locations.
However, for the success factor “Profit Margin” a signifi-
cant effect for geographic location was registered: higher
profit margins were declared by West German pharma-
cies (N = 218) than by East German pharmacies (N = 52).
Thus, the null hypothesis of a lack of difference is
rejected in part because economic success operatio-










































Figure 2 Results of the Structural Equation Model (SEM).
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eral states.
In many cases, the tests of the hypotheses showed a
disparity between the success factors “Net Revenue De-
velopment” and “Sales Profitability” and the strength of
the factors under investigation. In relation to this, the
realities of the regulations within the German pharmacy
market are briefly outlined in the introduction and be-














0.63 0.89 0.71 0.71
Competitive
situation
0.61 0.60 0.47 0.34
Turnover/
volume
0.73 0.85 0.67 0.59




0.71 0.55 0.43 0.44power and the opposite effects in the segment of pre-
scription pharmaceutical products (Rx) and the self-
medication segment (OTC) of the pharmacies. To some
extent, these opposing effects reflect the principle of
solidarity and the resulting moral hazard [26,47]. On the
one hand, description of purchasing power in this study
emphasizes the declining development of the self-
medication market. This indication runs contrary to
opinions expressed in the literature in the context of the
postulated increase in patient autonomy and the growing
self-medication market supposed to result from this
[3,44,45]. On the other hand, the results for purchasing
power and the often postulated patient autonomy at
least allow the hypothesis that the trend towards a grow-
ing patient autonomy is linked to household budgets.Table 5 Non-significant effects
Construct/variables Effects
Competitive situation OTC 0.06
Competitive situation Strategic management 0.08
Turnover/volume OTC 0.08
OTC Strategic management 0.04
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ment is quite strong (R = 0.22, p < 0.001). It remains to
be seen what influence AMNOG will have on profit
margins. With AMNOG, a new distribution remuner-
ation system for the wholesale trade was introduced as
of 1 January 2012, comparable to the systematization of
distribution remuneration for pharmacies in the so-
called combi-model. The combi-model for the wholesale
trade consists of a percentage surcharge of 3.15% and a
fixed remuneration of EUR 0.70 per package with an
upper limit of EUR 37.80. Currently, pharmaceutical
wholesalers are using these changes to make consider-
able reductions in discounts, although the revision leads
to a loss in margin for wholesale pharmaceuticals only
from a manufacturer price of upwards of EUR 18.19.
Due to the turnover structure of many pharmacies with
a major drug share in the segment up to EUR 18.19, the
reduction in discounts is not understandable. The influ-
ence of the revision in the distribution remuneration of
pharmaceutical wholesalers on the OTC proportion in
pharmacies in a statistical sense remains to be seen.
The missing correlation between membership in a phar-
macy cooperation and a higher profit margin contradicts
traditional economic theory. A possible explanation can
be deduced from the behavioural assumptions and the ef-
ficiency criterion of transaction cost theory, as well as the
conflict between “reduction in uncertainty” and “loss of
autonomy” from the perspective of resource dependency.
The efficiency criterion assumes the traceability or transpar-
ency of the benefits derived from pharmacy cooperation. In
the simplest case of a purchasing alliance, the apparent lack
of transparency of the purchasing advantages could be an in-
dication of pharmacists’ perceptions of cooperation. If a pur-
chasing advantage is in principle easy to measure, in the
regulatory context of the pharmacy market it is nonetheless
difficult to indicate the economic significance to members.
Transparency, in terms of perception, gains an additional di-
mension in this connection. The behavioural dimension of
opportunistic behaviour in transaction cost theory and the
loss of autonomy from the perspective of resource depend-
ence offer – through a common intersection – another po-
tential explanatory approach. Potentially, the interests of the
individual members of a pharmacy cooperation do not have
priority, but rather those of the cooperation do.
The SEM shows that there are reflective indicators,
such as self-perceived innovativeness, the development
of customer orientation/loyalty, customer loyalty and of-
fensive attitude, which are correlated with the construct
“Active Customer-Orientated Management”. Further-
more, the SEM, with the respective effect sizes of the
manifest variables on the latent construct “Economic
Success” illustrate especially the relationship between
“Competitive Situation”, “Turnover/Volume” and “Active
Customer-Orientated Management”.However, our study faces a number of shortcomings.
First, the sample size of 289 is only 1.33% of the total
number of public pharmacies in Germany. In part we
compensated for this shortcoming by using the soft
modelling statistical package, NEUSREL. However, there
is no other recent study with such a high number of
questionnaires available for evaluation or that has
constructed an SEM to assess “Economic Success” in the
German public pharmacy market.
Another shortcoming is that we focused primarily on
the self-perceptions of owners of public pharmacies. One
might assume that objective facts would lead to results
that are more reliable than subjective self-perceptions.
However, it is clear that the perceptions of pharmacists
drive decisions, not objective facts, particularly if the deci-
sion makers are not fully aware of these aspects. Thus,
stressing self-perceptions is indeed the most appropriate
way to determine the driving factors. The comments from
the pre-test were incorporated into the questionnaire and
thus all items were formulated clearly and easy to under-
stand. Furthermore, particular attention was paid to en-
suring that theoretical and content-relevant aspects were
duly recorded. The reply density of all items, including
open questions, was thoroughly reviewed by the pharma-
cists. There was no reference to a lack of comprehensibil-
ity in the questionnaire or similar signals for artefacts,
such as distortions in the phenomenon “Social Desirabil-
ity”. The response bias or non-response bias in the frame-
work of a survey with specialists can be disregarded [48].
In relation to the second level, the inquiry mode, we
employed a questionnaire with predominantly standardized
elements and thus it is certainly comparable to classic
Likert scales. Such scales capture the degree of agreement
or disagreement with given statements according to various
response categories. These response categories always com-
prise an ordinal form of measurement and thus obtaining
interval-level information is not possible. Consequently,
and in line with a strict interpretation, only statistical proce-
dures that are designed to process ordinal data can be used.
However, irrespective of the nature of the data collected by
means of a scale close to the Likert model, another imple-
mentation of scale requirements predominates in the meth-
odological social sciences literature: often “scales are used
which are only believed to be interval-scaled” [49].
Conclusions
The public pharmacy market in Germany has been fa-
cing increasing deregulation. It was initially expected
that this would lead to competitive pressure and to an
increased competitive orientation on the part of public
pharmacies. However, this study indicates that the
healthcare reforms of the last 10 years have not necessarily
and not generally increased the orientation of public
pharmacists towards competition and the application of
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macies which are rather active and customer-orientated,
others behave and feel as if they still live in the era of mon-
opolies in their local pharmaceutical markets. Customer-
orientated pharmacies try to bind their customers to them
(customer loyalty), show a higher level of a proactive atti-
tude and future orientation, and invest in efforts to increase
customer satisfaction. This study confirms that these phar-
macies have a higher turnover and a (slightly) higher profit
margin. As our analysis predominantly shows correlations
but no causality, we must be careful not to over-interpret
these findings. However, it seems quite reasonable to con-
clude that public pharmacies can increase their turnover
and their profit margins by showing a more strategic and
management-oriented attitude. Thus, pharmacists could
benefit from training programmes in entrepreneurship and
management.
On the basis of this study, we also recognize that there is
no North–South or East–West dichotomy with any out-
standing influence. It seems that the “global” location of the
pharmacy does not strongly determine economic success.
Only the success factor “Sales Profitability” depends on the
location, i.e. “West Pharmacies” (N = 218) declare a higher
sales profitability than “East Pharmacies” (N = 52). Based
on these findings, we can conclude that there is scope for
successful business in public pharmacies in every state in
Germany. Whether a public pharmacy is profitable seems
to depend more on the business-orientation of its owner
than on its location in the North/South or West/East.
Finally, we can conclude that even under increased
pressure from future healthcare reforms, there is still
sufficient space to serve the catchment population and
make a profit if public pharmacists learn the essentials
of strategic management.
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